Literature DB >> 30711301

Psychosocial issues in erythropoietic protoporphyria - the perspective of parents, children, and young adults: A qualitative study.

Hetanshi Naik1, Shruti Shenbagam2, Allysa Marie Go2, Manisha Balwani3.   

Abstract

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare photodermatoses, generally presenting in childhood with severe and painful phototoxicity. EPP has been reported to negatively affect quality of life (QoL), but there is limited information on the psychosocial issues faced by patients and families. To address this, an online focus group study was conducted to explore the perspective of parents of children with EPP, and young adults and children with EPP. Five focus groups were conducted in a semi-structured format, with moderator-led discussions exploring the impact on QoL. Three focus groups included parents of children with EPP, one with children aged 10-11 years, and another with young adults aged 24-25 years, for a total of 24 participants. Thematic data analysis showed that parents experience guilt for being unable to protect their children and frustration with the current state of knowledge of EPP. Parents also admitted that the disease can lead to stress within family members which is difficult to manage. Young adults expressed embarrassment over having to explain the disease to others. They reported that the teenage years were the most difficult to navigate; however, they learned to adapt to their disease as they grew older. Children expressed that they had limited understanding of their disease and wished they were told what symptoms to expect by physicians earlier in life. Our findings emphasize the significant impact on QoL for these families and a lack of age appropriate information for children with EPP. These findings can help improve counseling and support resources for patients and caregivers.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EPP; Erythropoietic protoporphyria; Focus groups; Psychosocial experiences; Quality of life

Mesh:

Year:  2019        PMID: 30711301      PMCID: PMC6660424          DOI: 10.1016/j.ymgme.2019.01.023

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

1.  Porphyrias: photosensitivity and phototherapy.

Authors:  M B Poh-Fitzpatrick
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.

Authors:  Manisha Balwani; Hetanshi Naik; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Jessica R Overbey; Bruce Wang; Ashwani K Singal; Lawrence U Liu; Robert J Desnick
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

3.  Delayed diagnosis and diminished quality of life in erythropoietic protoporphyria: results of a cross-sectional study in Sweden.

Authors:  J Frank; P Poblete-Gutiérrez
Journal:  J Intern Med       Date:  2010-11-14       Impact factor: 8.989

4.  Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life.

Authors:  S A Holme; A V Anstey; A Y Finlay; G H Elder; M N Badminton
Journal:  Br J Dermatol       Date:  2006-09       Impact factor: 9.302

5.  Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.

Authors:  Hetanshi Naik; Mikayla Stoecker; Saskia C Sanderson; Manisha Balwani; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-08-24       Impact factor: 4.797

6.  Women's experience of suffering repeated severe attacks of acute intermittent porphyria.

Authors:  A Wikberg; L Jansson; F Lithner
Journal:  J Adv Nurs       Date:  2000-12       Impact factor: 3.187

7.  Erythropoietic protoporphyria: a study of its psychosocial aspects.

Authors:  E A Rufener
Journal:  Br J Dermatol       Date:  1987-05       Impact factor: 9.302

8.  A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda.

Authors:  J Andersen; E Gjengedal; S Sandberg; M Råheim
Journal:  Br J Dermatol       Date:  2014-11-27       Impact factor: 9.302

9.  Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations.

Authors:  Amy Simon; Farrah Pompilus; William Querbes; Alex Wei; Sara Strzok; Craig Penz; Desiree Lyon Howe; Jessica R Hungate; Jae B Kim; Sonalee Agarwal; Patrick Marquis
Journal:  Patient       Date:  2018-10       Impact factor: 3.883

Review 10.  Erythropoietic protoporphyria.

Authors:  Mario Lecha; Hervé Puy; Jean-Charles Deybach
Journal:  Orphanet J Rare Dis       Date:  2009-09-10       Impact factor: 4.123

View more
  5 in total

Review 1.  Parental Stress and Quality of Life in Chronic Childhood Dermatoses: A Review.

Authors:  Debatri Datta; Rashmi Sarkar; Indrashis Podder
Journal:  J Clin Aesthet Dermatol       Date:  2021-09-01

Review 2.  Psychological Aspect and Quality of Life in Porphyrias: A Review.

Authors:  Granata Francesca; Annamaria Nicolli; Alessia Colaiocco; Elena Di Pierro; Giovanna Graziadei
Journal:  Diagnostics (Basel)       Date:  2022-05-10

3.  Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria.

Authors:  Hetanshi Naik; Jessica R Overbey; Robert J Desnick; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Bruce Wang; Ashwani Singal; Manisha Balwani
Journal:  JIMD Rep       Date:  2019-09-14

4.  Alternative Pathway Involvement in Protoporphyria Patients Related to Sun Exposure.

Authors:  Francesca Granata; Lorena Duca; Valentina Brancaleoni; Silvia Fustinoni; Giacomo De Luca; Irene Motta; Giovanna Graziadei; Elena Di Pierro
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

5.  The Patient Perspective: A Matter of Minutes.

Authors:  Rocco Falchetto
Journal:  Patient       Date:  2020-02       Impact factor: 3.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.